← Back to Clinical Trials
Recruiting NCT06074666

NCT06074666 Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06074666
Status Recruiting
Phase
Sponsor Roswell Park Cancer Institute
Condition Acute Lymphoblastic Leukemia, Pediatric
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-11-07
Primary Completion 2027-10-01

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 9 Years
Study Type INTERVENTIONAL
Interventions
CareMeds InterventionUsual Care Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-11-07 with a primary completion date of 2027-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA.

Eligibility Criteria

Inclusion Criteria: * Parent of a child who is diagnosed and being treated for any type of acute lymphoblastic leukemia (ALL) at a study site. * Parent has primary medication responsibility. * Pediatric patient aged 3-9 years * Child on therapy that includes home-based oral anti-cancer medication, such as 6-MP. * Parent has verbal English or Spanish fluency. * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * Parent is unwilling or unable to follow protocol requirements

Contact & Investigator

Central Contact

Elizabeth Bouchard, PhD

✉ Elizabeth.Bouchard@roswellpark.rog

📞 716-845-1300

Principal Investigator

Elizabeth Bouchard, PhD

PRINCIPAL INVESTIGATOR

Roswell Park Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT06074666 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 9 Years, studying Acute Lymphoblastic Leukemia, Pediatric. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06074666 currently recruiting?

Yes, NCT06074666 is actively recruiting participants. Contact the research team at Elizabeth.Bouchard@roswellpark.rog for enrollment information.

Where is the NCT06074666 trial being conducted?

This trial is being conducted at Buffalo, United States.

Who is sponsoring the NCT06074666 clinical trial?

NCT06074666 is sponsored by Roswell Park Cancer Institute. The principal investigator is Elizabeth Bouchard, PhD at Roswell Park Comprehensive Cancer Center. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology